ABL Diagnostics Société anonyme
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more
ABL Diagnostics Société anonyme (9BK0) - Total Liabilities
Latest total liabilities as of December 2024: €4.32 Million EUR
Based on the latest financial reports, ABL Diagnostics Société anonyme (9BK0) has total liabilities worth €4.32 Million EUR as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ABL Diagnostics Société anonyme - Total Liabilities Trend (2021–2024)
This chart illustrates how ABL Diagnostics Société anonyme's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ABL Diagnostics Société anonyme Competitors by Total Liabilities
The table below lists competitors of ABL Diagnostics Société anonyme ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DBS GROUP HLDGS
MU:DEVL
|
Germany | €722.15 Billion |
|
Jet.AI Inc.
NASDAQ:JTAI
|
USA | $3.66 Million |
|
BORGWARNER
BE:BGW
|
Germany | €8.79 Billion |
|
KOMATSU (KOM1.SG)
STU:KOM1
|
Germany | €2.44 Trillion |
|
ROCKWOOL INT. -B- - Dusseldorf Stock Exchang
DU:R90
|
Germany | €799.00 Million |
|
Land & Homes Group Ltd
AU:LHM
|
Australia | AU$36.13 Million |
|
Hakken Capital Corp
V:HAKK-P
|
Canada | CA$27.13K |
|
Pacific Bay Minerals Ltd
PINK:PBMFF
|
USA | $666.22K |
Liability Composition Analysis (2021–2024)
This chart breaks down ABL Diagnostics Société anonyme's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ABL Diagnostics Société anonyme's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ABL Diagnostics Société anonyme (2021–2024)
The table below shows the annual total liabilities of ABL Diagnostics Société anonyme from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €4.32 Million | -46.86% |
| 2023-12-31 | €8.14 Million | -5.99% |
| 2022-12-31 | €8.65 Million | +9081.14% |
| 2021-12-31 | €94.26K | -- |